Problématique duDiagnostic du VIH en Afrique Subsaharienne: Résultats Erronés dans une Etude Pilote (NAMSAL) au Cameroun
Health sci. dis
;
23(8): 22-26, 2022. tables
Article
in English
| AIM
| ID: biblio-1391082
ABSTRACT
Introduction.The NAMSAL therapeutic trial evaluated the non-inferiority of a first line treatment comprising Dolutegravir to another line comprising Efavirenz 400. The criteria for not taking part to the trial included infection with non-M HIV-1, untreated patients with HIV viral load <1000 copies/mL. The objective of this study was to explain why some treatment naïve patients had undetectable viral loads. Materials and methods. Out of 817 patients pre-included with HIV-1 infection and untreated, 204 were not included and the present study focused on 114 of these 204 patients not included in NAMSAL. HIV plasma viral load, serological status and the serotype were confirmed by RT-qPCR (Abbott), INNOLIA HIVI/II Score (Fujirebio), and by ELISA with synthetic peptides of thedifferent HIV-1&2 groups. Universal or specific PCR (M and O) were performed on the samples for molecular confirmation and characterization. Results. Amongthe 114 patients studied, 49 (43%) had a viral load < 1000 copies/mL and 65 (57%) had a viral load > 1000 copies/mL. When reported to the whole cohort of pre-included patients (n=817), 4/817 (0.5%) were group-O confirmed by molecular biology. Based on the PCR results, 14 out of 817 patients (1.7%) deemed to be HIV-1 positive were most likely uninfected. Conclusion. 1.7% of HIV-1 patients referred for inclusion in NAMSAL were not actually infected. Ongoing staff training and quality control of laboratories must be strengthened in Cameroon in view of the social and economic consequences of misdiagnosis.
Full text:
Available
Index:
AIM (Africa)
Main subject:
Therapeutics
/
Diagnosis
/
HIV Testing
Type of study:
Diagnostic study
Language:
English
Journal:
Health sci. dis
Year:
2022
Type:
Article
Institution/Affiliation country:
Centre de Recherche sur les Maladies Emergentes et Réémergentes (CREMER), Virology Laboratory IMPM-IRD, IMPM/CM
/
Centre de Recherche sur les Maladies Emergentes et Réémergentes (CREMER), Virology Laboratory IMPM-IRD, IMPM,/CM
/
Département de Pharmacie Galénique et Législation Pharmaceutique de la FMSB/CM
/
Hôpital Central, Yaoundé/CM
/
Sub-division Medical Center of Barak/CM
/
TransVIHMI, Institut de Recherche pour le Développement (IRD), INSERM/FR
/
TransVIHMI, Institut de Recherche pour le Développement (IRD), INSERM, Université de Montpellier/FR
Similar
MEDLINE
...
LILACS
LIS